Drug Profile

BVA 201

Alternative Names: BVA-201

Latest Information Update: 19 Oct 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Biovista
Class Neuroprotectants
Mechanism of Action Antioxidants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes

Highest Development Phases

Preclinical Multiple sclerosis

Most Recent Events

19 Oct 2024 BVA 201 is still in preclinical development for Multiple-sclerosis in USA (Biovista Pipeline, October 2024)
19 Oct 2024 Biovista plans the Proof of Concept (PoC) studies of BVA 201 in man (Biovista Pipeline, October 2024)
28 Jun 2024 No recent reports of development identified for preclinical development in Multiple-sclerosis in USA

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com